Program Description
The diagnosis of human epidermal growth factor receptor 2-positive metastatic breast cancer has historically been associated with poor clinical outcomes. The use of monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates has impacted patient care. Novel targeted therapies and combinations of treatments are now used in practice, and pharmacists are well-positioned to assist in therapy selection. This activity will focus on updates in clinical practice guidelines and will review strategies for treatment selection and sequencing, potential drug resistance, and patient-specific considerations. Additionally, the faculty will review challenging patient cases to reinforce key principles and nuances with therapy.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 16, 2022
Expiration date: August 16, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Personalize treatment plans for a patient with human epidermal growth factor receptor 2 (ERBB2)-positive breast cancer based on disease- and patient-specific factors
- Determine optimal adjuvant treatment strategies for ERBB2-positive breast cancer
- Construct a plan for sequencing drug therapies for ERBB2-positive breast cancer, accounting for safety, efficacy, and patient specifics
Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania
Heather Moore, PharmD, BCOP, CPP
Clinical Oncology Pharmacist, Breast Oncology
Duke University Hospital
Durham, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-189-L01-P. The activity is available for CE credit through August 16, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, watch the presentation in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Heather Moore, PharmD, BCOP, CPP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Novartis, Lilly, AstraZeneca, Daiichi Sankyo, Seagen
Danielle Roman, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Meg Croom Taylor, PharmD, CPP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms